Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

Nature Medicine

Volumn 11, Issue 1, 2005, Pages 77-84

  Nebbioso, Angela ^a   Clarke, Nicole ^b   Voltz, Emilie ^b   Germain, Emmanuelle ^b   Ambrosino, Concetta ^a   Bontempo, Paola ^a   Alvarez, Rosana ^c   Schiavone, Ettore M ^d   Ferrara, Felicetto ^d   Bresciani, Francesco ^a   Weisz, Alessandro ^a   De Lera, Angel R ^c   Gronemeyer, Hinrich ^b   Altucci, Lucia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITY OF VIGO   (Spain)

^d CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEATH; DNA MODIFICATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION; KARYOTYPE; MALE; MATURATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; STEM CELL;

ACUTE DISEASE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 13444306459     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1161     Document Type: Article

References (30)

1. Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
2. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299 (2002).
3. Egger, G., Liang, G., Aparicio, A. & Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
4. Vigushin, D.M. & Coombes, R.C. Targeted histone deacetylase inhibition for cancer therapy. Curr. Cancer Drug Targets 4, 205-218 (2004).
5. Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110-3115 (2001).
6. Ferrara, F.F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
7. Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
8. Phiel, C.J. et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741 (2001).
9. Amin, H.M., Saeed, S. & Alkan, S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br. J. Haematol. 115, 287-297 (2001).
10. Suzuki, T. et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42, 3001-3003 (1999).
11. Saito, A. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999).
12. Rosato, R.R., Almenara, J.A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637-3645 (2003).
13. Richon, V.M., Sandhoff, T.W., Rifkind, R.A. & Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019 (2000).
14. Glaser, K.B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163 (2003).
15. Sasakawa, Y. et al. Effects of FK22B, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64, 1079-1090 (2002).
16. Clarke, N., Jimenez-Lara, A.M., Voltz, E. & Gronemeyer, H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23, 3051-3060 (2004).
17. Ammanamanchi, S., Freeman, J.W. & Brattain, M.G. Acetylated sp3 is a transcriptional activator. J. Biol. Chem. 278, 35775-35780 (2003).
18. Bouwman, P. & Philipsen, S. Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 195, 27-38 (2002).
19. Braun, H., Koop, R., Ertmer, A., Nacht, S. & Suske, G. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 29, 4994-5000 (2001).
20. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
21. Litwack, G. (ed.) Vitamins and Hormones: TRAIL, 448 pages (Academic Press, 2004).
22. Kelley, S.K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333-339 (2004).
23. Altucci, L. & Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1, 181-193 (2001).
24. Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7, 680-686 (2001).
25. Ryu, H. et al. Histone deacetyase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. USA 100, 4281-4286 (2003).
26. Camarero, N., Nadal, A., Barrero, M.J., Haro, D. & Marrero, P.F. Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site. Nucleic Acids Res. 31, 1693-1703 (2003).
27. Won, J., Yim, J. & Kim, T.K. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem. 277, 38230-38238 (2002).
28. Rosato, R.R., Almenara, J.A., Dai, Y. & Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273-1284 (2003).
29. Brummelkamp, T.R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
30. Shiohara, M. et al. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. Blood 93, 2057-2066 (1999).